January 8, 2015
Financial and Pharma Executives to Discuss How Investors Will Perceive Value in 2015 at Annual Biotech Showcase™
BURLINGTON, Mass., Jan. 7, 2015 -- inVentiv Health, a life science knowledge and services company, will moderate a panel of senior financial and pharmaceutical executives during this year's Biotech Showcase™, exploring how investors in 2015 will perceive value and the pitfalls companies must avoid in creating value that attracts investors.
Michael Griffith, Executive Vice President at inVentiv Health and President of the Commercial Division, will host and moderate the luncheon panel, Value Creation: Private and Public Investment Strategies and Stage Gates for Success. This 90-minute panel begins at noon on January 12th at the Parc 55 Hotel in the Cyril Magnin Ballroom, 55 Cyril Magnin Street in San Francisco.
Griffith and his fellow panelists will explore how various stakeholders place value on assets during each of the various phases of development. There is no longer a single set of criteria for evaluating pharma/biotech investments and evolving market dynamics place far greater emphasis on product innovation as a driver of value. The panel will explore obstacles for companies to avoid on the path to acquisition, partnership or joint commercialization models.
"Biopharmaceutical companies know that to win in today's complex, global marketplace, they need to redefine how they commercialize assets," Griffith said. "They need a better model that provides comprehensive commercial capabilities realizing efficiencies to accelerate performance and delivery. Enhanced commercialization leads to enhanced value."
For the first time this year, inVentiv Health will be introducing to the larger marketplace its Contract Commercial Organization (CCO), a unique business model that was developed in response to the industry looking for a better way to commercialize assets that is flexible, scalable, innovative and more effective at value creation. For the past four years, many of the company's largest clients have made use of its comprehensive continuum of services, which begins in early stage drug development and extends through launch and all aspects of product commercialization.
Companies who broadly outsource commercialization to inVentiv Health are able to gain instant access to global reach, broad therapeutic expertise, and premium services.
Both emerging and established biopharmaceutical companies look to inVentiv Health for complementary expertise, high-value strategic insights and essential speed. Mid-size innovator companies partner with inVentiv Health for full commercialization capabilities that allow them to retain the value of their asset.
"We invested in developing the infrastructure to deliver our CCO model in a streamlined fashion with a single point of contact. We offer expertise across the lifecycle of a product, which is powered by a team entirely aligned with our clients' commercial objectives," added Griffith.
Now in its seventh year, Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to meet with investors and biopharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. The meeting takes place in San Francisco January 12-14, concurrent with the J.P. Morgan Healthcare Conference, a gathering of executives from around the world. Meetings during this week help set the investment tone for the coming year.
Biotech Showcase™ delegates include biopharmaceutical and life science company executives, investors in private and public companies, sector analysts, bankers and industry professionals.
About inVentiv Health
inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our clients' development and commercialization goals. With more than 13,000 employees supporting clients in 70 countries, our global scale and broad expertise make us an attractive strategic partner for companies seeking to get medicines to patients in a complex operating, regulatory and reimbursement environment. inVentiv Health's clients include more than 550 life sciences companies, including all 20 of the largest biopharmaceutical companies in the world. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health transforms promising ideas into commercial reality for the financial success of our clients and the delivery of better treatments to patients worldwide. For more information, visit www.inVentivHealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays, cancellations and terminations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of our acquisition of Catalina Health Resource, LLC and any future acquisitions; the impact of any change in our current credit ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact on pharmaceutical manufacturers, including pricing pressures, from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth, including through outsourced service providers; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our clients, including the impact of the final HIPAA Privacy Rule on the willingness of pharmaceutical manufacturers to sponsor patient adherence programs; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel; any potential impairment of goodwill or intangible assets and the factors leading to such impairments; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.
SOURCE inVentiv Health, Inc.